Can you take Selank and Semax together?

There is no specific, well-documented interaction rule for combining Selank and Semax in the aggregated research reviewed. Combining peptides should only be considered under professional supervision. This is not medical advice.

Which is better researched, Selank or Semax?

Selank is currently research-stage and Semax is investigational (in trials). "Better researched" depends on your research goal — review each profile's cited sources.

Nootropic & Cognitive · Comparison

Selank vs Semax

Q: What is the difference between Selank and Semax?

Selank: Selank is a synthetic heptapeptide derived from tuftsin, an endogenous immunomodulatory peptide. Developed in Russia by the Institute of Molecular Genetics, it has been studied extensively for anxiolytic, nootropic, and immunomodulatory effects. It is registered as a medication in Russia and Ukraine. Semax: Semax is a synthetic heptapeptide derived from adrenocorticotropic hormone (ACTH) — specifically the 4–7 fragment modified with a C-terminal Pro-Gly-Pro extension for stability. Developed in Russia in the 1980s and used clinically there for stroke recovery, cognitive enhancement, and neuroprotection, it is one of the most researched nootropic peptides with a decades-long safety record in Eastern European clinical practice. Its primary mechanism involves potent upregulation of BDNF (Brain-Derived Neurotrophic Factor). Both are in the Nootropic & Cognitive category but differ in mechanism, dosing, and research evidence — see the full comparison.

A neutral, side-by-side comparison of two nootropic & cognitive peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.

Selank

Research-stage

Selank is a synthetic heptapeptide derived from tuftsin, an endogenous immunomodulatory peptide. Developed in Russia by the Institute of Molecular Genetics, it has been studied extensively for anxiolytic, nootropic, and immunomodulatory effects. It is registered as a medication in Russia and Ukraine.

Full profile

Semax

Investigational (in trials)

Semax is a synthetic heptapeptide derived from adrenocorticotropic hormone (ACTH) — specifically the 4–7 fragment modified with a C-terminal Pro-Gly-Pro extension for stability. Developed in Russia in the 1980s and used clinically there for stroke recovery, cognitive enhancement, and neuroprotection, it is one of the most researched nootropic peptides with a decades-long safety record in Eastern European clinical practice. Its primary mechanism involves potent upregulation of BDNF (Brain-Derived Neurotrophic Factor).

Full profile

	Selank	Semax
Category	Nootropic & Cognitive	Nootropic & Cognitive
Also known as	TP-7, Tuftsin analog	ACTH(4-7)PGP, Met-Glu-His-Phe-Pro-Gly-Pro
Evidence	Research-stage	Investigational (in trials)
Dosing range	250mcg–1000mcg mcg, 1–2x daily	200mcg–900mcg mcg, Once or twice daily (intranasal most common)
Administration	Intranasal (most common — direct CNS delivery), Subcutaneous injection	Intranasal (preferred — high CNS bioavailability), Subcutaneous injection
Key side effects	Mild sedation at high doses, Nasal irritation (intranasal route), Generally very well-tolerated, No reported dependence or withdrawal	Mild anxiety or restlessness at high doses, Nasal irritation (intranasal route), Increased energy / difficulty sleeping if dosed too late in the day, Mild appetite suppression
Cited sources	1 reference	3 references

Key differences

Evidence level differs: Selank is research-stage, while Semax is investigational (in trials).
Administration: Selank — Intranasal (most common — direct CNS delivery), Subcutaneous injection; Semax — Intranasal (preferred — high CNS bioavailability), Subcutaneous injection.
Frequency: Selank is typically 1–2x daily; Semax is Once or twice daily (intranasal most common).
Research depth: this profile cites 1 source for Selank vs 3 for Semax.

How each works

Selank

Selank modulates GABA-A receptors and influences BDNF expression, producing anxiolytic effects comparable to benzodiazepines without sedation or dependence. Russian clinical studies report improvements in generalized anxiety disorder, cognitive performance, and mood stability. It also appears to modulate T-helper cell ratios and interferon production.

Semax

Semax increases BDNF expression in the hippocampus and frontal cortex by 1.3–1.6x at research doses in rodent models. It also upregulates NGF (nerve growth factor) and modulates serotonin, dopamine, and NMDA receptor systems. Russian clinical data (not yet replicated in Western trials) suggests efficacy in ischemic stroke recovery, ADHD, glaucoma, and cognitive decline. The Pro-Gly-Pro C-terminal extension dramatically improves resistance to enzymatic degradation compared to native ACTH(4-7).

Read the full Selank profile Read the full Semax profile

This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.